RAAPID vs Xsolis (2026)
Two vendors applying models where clinical documentation turns into money, and both have unusually good structural answers. RAAPID links every suggested condition code back to specific clinical evidence, which makes explainability a property of the architecture rather than a claim, with coder validation built into the workflow. Xsolis scores medical necessity continuously and sits between payer and provider so both argue from the same number, with peer reviewed research behind that score. Neither is doing anything improper and both are better documented than their peers. What neither publishes is the calibration figure for its own side, the codes removed against codes added for one, and the appeal overturn rate for the other, and those two numbers are what separate a defensible system from a productive one.
- The explainability architecture is structural: every suggested condition code links back to specific clinical evidence, with coder validation inside the workflow.
- Both major security credentials are held and the deployment disclosure is the strongest encountered in this part of the index.
- For an organisation that must defend added conditions in an audit, evidence linkage is a better answer than an accuracy claim.
- It sits between payer and provider rather than serving one side, scoring medical necessity continuously so both parties argue from the same number.
- It is the only vendor in that cluster with peer reviewed research behind its score, published across multiple health systems.
- A risk based certification at the two year tier is the strongest security posture in this part of the index.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. RAAPID and Xsolis are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | RAAPID | Xsolis |
|---|---|---|
| Primary category | Value Based Care Intelligence | RCM & Prior Auth AI |
| Founded | 2022 | Not recorded |
| Headquarters | Louisville, Kentucky, United States | Franklin, Tennessee |
| Website | raapidinc.com | xsolis.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards RAAPID its top capability grade on AI Centrality and Deployment Model and Data Residency. Set against Xsolis, RAAPID grades higher on FDA and Regulatory Status, Deployment Model and Data Residency and Commercial Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Xsolis its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against RAAPID, Xsolis grades higher on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose RAAPID or Xsolis?
On the axes where the AI Health Index separates them, RAAPID grades higher on FDA and Regulatory Status, Deployment Model and Data Residency and Commercial Transparency, and Xsolis grades higher on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Xsolis leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do RAAPID and Xsolis differ most?
The widest separation the AI Health Index records between RAAPID and Xsolis is on Deployment Model and Data Residency, where RAAPID grades A and Xsolis grades C. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do RAAPID and Xsolis grade the same?
The AI Health Index grades RAAPID and Xsolis the same on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both apply models to decisions with money attached and neither publishes its calibration: for risk adjustment that is the ratio of codes removed to codes added, and for medical necessity it is the proportion of AI informed adverse determinations overturned on appeal. RAAPID's evidence is specific and quantified but entirely vendor reported with no independent validation located. Neither publishes a bias evaluation or subgroup analysis, and utilization management is the one lane in this index where an output can end in care being denied.